Literature DB >> 28735069

Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group.

Nicolas Penel1, Axel Le Cesne2, Sylvie Bonvalot3, Antoine Giraud4, Emmanuelle Bompas5, Maria Rios6, Sébastien Salas7, Nicolas Isambert8, Pascaline Boudou-Rouquette9, Charles Honore2, Antoine Italiano10, Isabelle Ray-Coquard11, Sophie Piperno-Neumann12, François Gouin13, François Bertucci14, Thomas Ryckewaert15, Jean-Emmanuel Kurtz16, Françoise Ducimetiere11, Jean-Michel Coindre17, Jean-Yves Blay11.   

Abstract

PURPOSE: The outcome of desmoid-type fibromatosis (DTF) is unpredictable. Currently, a wait-and-see approach tends to replace large en bloc resection as the first therapeutic approach. Nevertheless, there are no validated factors to guide the treatment choice.
METHOD: We conducted a prospective study of 771 confirmed cases of DTF. We analysed event-free survival (EFS) based on the occurrence of relapse after surgery, progressive disease during the wait-and-see approach, or change in therapeutic strategy. Identification of prognostic factors was performed using classical methods (log-rank test and Cox model).
RESULTS: Overall, the 2-year EFS was 56%; this value did not differ between patients undergoing an operation and those managed by the wait-and-see approach (53% versus 58%, p = 0.415). In univariate analysis, two prognostic factors significantly influenced the outcome: the nature of diagnostic sampling (p = 0.466) and primary location (p = 0.0001). The 2-year EFS was only 32% after open biopsy. The 2-year EFS was 66% for favourable locations (abdominal wall, intra-abdominal, breast, digestive viscera and lower limb) and 41% for unfavourable locations. Among patients with favourable locations, the 2-year EFS was similar in patients treated by both surgery (70%) and the wait-and-see approach (63%; p = 0.413). Among patients with unfavourable locations, the 2-year EFS was significantly enhanced in patients initially managed with the wait-and-see approach (52%) compared with those who underwent initial surgery (25%; p = 0.001).
CONCLUSION: The location of DTF is a major prognostic factor for EFS. If these findings are confirmed by independent analysis, personalised management of DTF must consider this easily obtained parameter.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Desmoid-type fibomatosis; Nationwide cohort; Prognostic factors; Surgery; Wait and see

Mesh:

Year:  2017        PMID: 28735069     DOI: 10.1016/j.ejca.2017.06.017

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  39 in total

1.  Sorafenib for Advanced and Refractory Desmoid Tumors.

Authors:  Mrinal M Gounder; Michelle R Mahoney; Brian A Van Tine; Vinod Ravi; Steven Attia; Hari A Deshpande; Abha A Gupta; Mohammed M Milhem; Robert M Conry; Sujana Movva; Michael J Pishvaian; Richard F Riedel; Tarek Sabagh; William D Tap; Natally Horvat; Ethan Basch; Lawrence H Schwartz; Robert G Maki; Narasimhan P Agaram; Robert A Lefkowitz; Yousef Mazaheri; Rikiya Yamashita; John J Wright; Amylou C Dueck; Gary K Schwartz
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

2.  Postoperative radiotherapy in primary resectable desmoid tumors of the neck: a case-control study.

Authors:  Xiaoshuang Niu; Rui Jiang; Chaosu Hu
Journal:  Strahlenther Onkol       Date:  2019-06-06       Impact factor: 3.621

3.  Clinical features and treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan.

Authors:  Yoshihiro Nishida; Akira Kawai; Junya Toguchida; Akira Ogose; Keisuke Ae; Toshiyuki Kunisada; Yoshihiro Matsumoto; Tomoya Matsunobu; Kunihiko Takahashi; Kazuki Nishida; Toshifumi Ozaki
Journal:  Int J Clin Oncol       Date:  2019-07-22       Impact factor: 3.402

Review 4.  The Landmark Series: Desmoid.

Authors:  Marco Fiore; Aimee Crago; Rebecca Gladdy; Bernd Kasper
Journal:  Ann Surg Oncol       Date:  2021-01-01       Impact factor: 5.344

Review 5.  Locally Aggressive Connective Tissue Tumors.

Authors:  Mrinal M Gounder; David M Thomas; William D Tap
Journal:  J Clin Oncol       Date:  2017-12-08       Impact factor: 44.544

6.  MRI Volumetrics and Image Texture Analysis in Assessing Systemic Treatment Response in Extra-Abdominal Desmoid Fibromatosis.

Authors:  Ty K Subhawong; Katharina Feister; Kevin Sweet; Noam Alperin; Deukwoo Kwon; Andrew Rosenberg; Jonathan Trent; Breelyn A Wilky
Journal:  Radiol Imaging Cancer       Date:  2021-07

Review 7.  Desmoid Fibromatosis: Management in an Era of Increasing Options.

Authors:  Ravin Ratan; Christina L Roland; Andrew J Bishop
Journal:  Curr Oncol Rep       Date:  2021-03-14       Impact factor: 5.075

8.  Desmoid Type Fibromatosis of the Breast: Ten-Year Institutional Results of Imaging, Histopathology, and Surgery.

Authors:  Jörn Lorenzen; Miriam Cramer; Nina Buck; Kay Friedrichs; Kirsten Graubner; Clara Sonja Lühr; Christoph Lindner; Axel Niendorf
Journal:  Breast Care (Basel)       Date:  2020-05-28       Impact factor: 2.860

Review 9.  Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis.

Authors:  Monika Sparber-Sauer; Daniel Orbach; Fariba Navid; Simone Hettmer; Stephen Skapek; Nadège Corradini; Michela Casanova; Aaron Weiss; Matthias Schwab; Andrea Ferrari
Journal:  Br J Cancer       Date:  2021-03-15       Impact factor: 7.640

10.  Abscess or Tumor? When a Retroperitoneal Mass on Computerized Tomography Turns Out to Be a Rare Soft Tissue Growth.

Authors:  Ilya Noginskiy; Neil Nimkar; Madhumati R Kalavar
Journal:  Case Rep Oncol       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.